SlideShare a Scribd company logo
1 of 40
Download to read offline
NEPHROTIC SYNDROME
Arpita Halder
Definition
Nephrotic syndrome is a clinical complex characterized
by a number of renal and extrarenal features, most
prominent of which are
 Proteinuria (in practice > 3.0 to 3.5gm/24hrs),
 Hypoalbuminemia,
 Edema,
 Hypertension
 Hyperlipidemia,
 Lipiduria and
 Hypercoagulabilty.
Classification
Nephrotic syndrome can be
⦁ Primary, being a disease specific to the kidneys,
⦁ Secondary, being a renal manifestation of a systemic
general illness
Primary causes
Primary causes include-
⦁ Minimal-change nephropathy(70-90% children and 10-
15%inadult)
⦁ Focal glomerulosclerosis (15%inadult)
⦁ Membranous nephropathy (30%inadult)
⦁ Mesangial proliferative glomerulonephritis .
⦁ Rapidly progressive glomerulonephritis
Secondary causes
Secondary causes include-
⦁ Diabetes mellitus
⦁ Lupus erythematosus
⦁ Amyloidosis and paraproteinemias
⦁ Viral infections (eg, hepatitis B, hepatitis C, HIV )
⦁ Preeclampsia
⦁ Nephrotic syndrome is 15 times more common in
children
⦁ Most cases in children are due to minimal-change
disease.
⦁ In adults, the most common form is membranous
glomerulonephritis, followed by FSGS.
⦁ Diabetic nephropathy is emerging as a major cause of
nephrotic syndrome
Nephron
Normal glomerulus
Pathophysiology of proteinuria
⦁ In a healthy individual, less than 0.1%
of pl. albumin may traverse the
glomerular filtration barrier.
⦁ glomerular capillaries are lined by a
fenestrated endothelium that sits on
the glomerular basement membrane
⦁ Which in turn is covered by glomerular
epithelium, or podocytes, which
envelops the capillaries with cellular
extensions called foot processes. In
between the foot processes are the
filtration slits.
⦁ These 3 structures are the glomerular
filtration barrier
Pathophysiology of proteinuria
⦁ The glomerular structural changes that may cause proteinuria
are damage to the endothelial surface, the glomerular
basement membrane, or the podocytes.
⦁ Glomerular haemodynamics (Intraglomerular hypertension
and hyperfiltration) can alter Glomerular permeabiality.
⦁ Selectivity of proteinuria- Excretion of relatively low M.W.
protein (Albumin or transferrin) is known as selective
proteinuria while if excretion is predominately high M.W.
protein (IgG, IgM or α2 macroglobulin) it is nonselective
proteinuria.
⦁ It is also related to relative damage of Glomerular filter.
Hypoalbunemia
⦁ It is due to both the proteinuria and due to the increase
renal catabolism (in tubules).
⦁ In fact hepatic albumin synthesis is increased from
145±9mg/kg/day to 213±17mg/kg/day in nephrotic
patients.
Pathogenesis of edema
Metabolic consequences of proteinuria
Metabolic consequences of the nephrotic syndrome include
the following:
⦁ Infection
⦁ Hyperlipidemia and atherosclerosis
⦁ Hypocalcemia and bone abnormalities
⦁ Hypercoagulability
⦁ Hypovolemia
Proposed explanations of Infection in NS
Proposed explanations include the following:
⦁ Urinary immunoglobulin losses
⦁ Edema fluid acting as a culture medium
⦁ Protein deficiency
⦁ Decreased bactericidal activity of the leukocytes
⦁ Immunosuppressive therapy
⦁ Urinary loss of a complement factor (properdin factor B)
that opsonizes certain bacteria
Hypperlipedemia
⦁ Due to increase hepatic lipoprotein synthesis that is triggered
by reduced oncotic .
⦁ Defective lipid catabolism has also important role.
⦁ LDL and cholesterol are increased in majority of patients
whereas VLDL and triglyceride tends to rise in patients with
severe disease.
⦁ It increases the relative risk for MI 5.5 fold and coronary death
2.8 fold.
⦁ It also increases progression of renal disease
Hypercoagulability
⦁ Multifactorial in origin
⦁ Increase urinary loss of antithrombin III.
⦁ Altered levels and/or activity of protein C & S.
⦁ Hyperfibronogenemia due to increase hepatic synthesis.
⦁ Impaired fibrinolysis due to decrease plasminogen.
⦁ Increase platelet aggregability – relative immobility -
haemoconcentragtion from hypovolemia. – hyperlipidemia
⦁ Alteration in endothelial function
Hypocalcemia
⦁ Hypocalcemia is common in the nephrotic syndrome, but
rather than being a true hypocalcemia, it is usually
caused by a low serum albumin level.
⦁ Nonetheless, low bone density and abnormal bone
histology are reported in association with nephrotic
syndrome.
⦁ This could be caused by urinary losses of vitamin D–
binding proteins, with consequent hypovitaminosis D and,
as a result, reduced intestinal calcium absorption.
Hypovolemia
⦁ Hypovolemia occurs when hypoalbuminemia
decreases the plasma oncotic pressure,
⦁ Resulting in a loss of plasma water into the
interstitium and causing a decrease in circulating
blood volume.
⦁ Hypovolemia is generally observed only when the
patient's serum albumin level is less than 1.5 g/dL.
⦁ Hypotension is a late feature
FUNCTIONAL CONSEQUENCE OF URINARY
LOSS OF PLASMA PROTEIN
⦁ Thyroid binding globulins and thyroxin – may lead to
hypothyroidism.
⦁ Vit D binding protein – oesteomalacia, but rare
⦁ Total calcium is also low due to low albumin level.
⦁ Transferrin and erythropoietin and – microcytic
hypochromic anemia.
⦁ ARF – is rare in nephrotic syndrome. In whom it occur
patient are elderly of minimal changes disease / FGSS
Symptoms and signs
⦁ Include anorexia, malaise, puffy eyelids, retinal sheen, abdominal
pain, wasting of muscles, and edema.
⦁ Most often, the edema is mobile - detected in the eyelids in the
morning and in the ankles after ambulation
⦁ Focal edema may be the reason for seeking help
complaints as:
 difficulty breathing (pleural effusion or laryngeal edema),
 substernal chest pain (pericardial effusion),
 scrotal swelling,
 swollen knees (hydroarthrosis),
 swollen abdomen (ascites), and
for such
 abdominal pain from edema of the mesentery.
Symptoms and signs
⦁ An early sign of NS is frothy urine.
⦁ At presentation,proteinuria is usually > 2
gm/m2/day, or a urine protein/creatinine
ratio is > 2
⦁ Orthostatic hypotension and even shock
may develop in children.
⦁ Adults may be hypo-, normo-, or
hypertensive.
⦁ Oliguria and even
⦁ Acute renal failure may develop because
of hypovolemia and diminished
perfusion.
Symptoms and signs
⦁ Prolonged NS may result in nutritional
deficiencies, including protein malnutrition
⦁ ,myopathy,
⦁ Decreased total Ca++, tetany
⦁ Spontaneous peritonitis and opportunistic
infections
⦁ Coagulation disorders, with decreased
fibrinolytic activity
⦁ Episodic hypovolemia, are a serious
thrombotic risk ( renal vein thrombosis).
⦁ Hypertension with cardiac and cerebral
complications.
Differential Diagnosis
⦁ Heart failure
⦁ Cirrhosis
⦁ Glomerulonephritis
Workup
Diagnostic studies for nephrotic syndrome may include the
following:
⦁ Urinalysis
⦁ Urine sediment examination
⦁ Urinary protein measurement (24-hr)
⦁ Serum albumin
⦁ Serologic studies for infection and immune abnormalities
⦁ Renal ultrasonography
⦁ Renal biopsy
IMPORTANT DEFINITIONS
⦁ RESPONSE; protein free urine on 3 consecutive days within 7 days.
⦁ RELAPSE; protein +ve urine on 3 consecutive days within one week
with edema.
⦁ FREQUENT RELAPSING NS; steroid sensitive nephrotic syndrome
with 2 or more relapses in 6 months or more than 3 in one year.
⦁ STEROID DEPENDANT; responder who relapses while steroid is
being tapered or within 14 days of stopping steroid treatment.
⦁ INITIAL NON RESONDER; no response during initial 8 weeks of
therapy.
⦁ LATE NON RESPONDER; an initial steroid responder who fails to
respond to 4 week treatment in relapse.
Management
⦁ Specific treatment
⦁ In minimal-change nephropathy, glucocorticosteroids, such as prednisone,
are used. Children who relapse may be treated with rituximab]
⦁ In some lupus nephritis, prednisone and cyclophosphamide are useful
⦁ Secondary amyloidosis with nephrotic syndrome may respond to
inflammatory treatment of the primary disease.
anti-
⦁ In membranous nephropathy, expectant management without
immunosuppression can be used for the first 6 months, in patients at low risk
for progression (ie, those with serum creatinine level < 1.5 mg/dL). Patients
with renal insufficiency (serum creatinine level > 1.5 mg/dL) are at greatest
risk for the development of end-stage renal disease and should receive
immunosuppressive therapy.[37]
Management
Diet and activity
⦁ The diet in patients with nephrotic syndrome should provide
adequate energy (caloric) intake and adequate protein (1-2
g/kg/d).
⦁ A diet with no added salt will help to limit fluid overload.
⦁ Management of hyperlipidemia could be of some importance if
the nephrotic state is prolonged.
⦁ Fluid restriction per se is not required.
⦁ Ongoing activity, rather than bed rest, will reduce the risk of
blood clots.
Management
Acute Nephrotic Syndrome in Adults
⦁ Diuretics will be needed; furosemide, spironolactone, and even
metolazone may be used. Volume depletion may occur with diuretic
use, which should be monitored.
⦁ Anticoagulation has been advocated by some for use in preventing
thromboembolic complications,
⦁ Hypolipidemic agents may be used, but if the nephrotic syndrome
cannot be controlled, the patient will have persistent hyperlipidemia.
⦁ ACE inhibitors and/or ARB are widely used. These may reduce
proteinuria by reducing the systemic blood pressure, by reducing
intraglomerular pressure, and also by direct action on podocytes.
Management
⦁ Long-Term Monitoring- Follow-up care in patients with
nephrotic syndrome includes
⦁ Immunization,
⦁ Treatment of relapses of steroid-responsive nephrotic
syndromes,
⦁ Monitoring for steroid toxicity, and
⦁ Monitoring of diuretic and angiotensin antagonist
regimens.
Medication Summary
⦁ Corticosteroids (prednisone),
⦁ Cyclophosphamide,
⦁ Cyclosporine
⦁ Rituximab
⦁ Mycophenolate
⦁ Diuretics
⦁ ACE inhibitors and
⦁ ARB
NEPHROTIC SYNDROME
SOME COMMOM RENAL DISORDERS
MINIMAL CHANGE GN
⦁ Introduction Synonyms: Nil
disease, lipoid nephrosis, foot
process disease
⦁ Incidence: 80% of nephrotic
syndrome in children (1-8 yrs.),
mostly male. Adults in 2nd-3rd
decade
⦁ Etiology: Idiopathic. Loss of net
negative charge on capillary
basement membrane
⦁ Pathology: LM - Normal. IF -
Negative. EM - Focal fusion/loss of
foot processes.
MINIMAL CHANGE GN
⦁ Clinical Features: : Nephrotic syndrome. History of recent URI in
30%. Association with Hodgkin’s lymphoma Overlap with FSGS
patients
⦁ Lab Features: Selective proteinuria. No specific laboratory findings.
⦁ Clinical Course.. Spontaneous remission in 25-40%. Complete
remission in 65-70% of patients. Steroid resistant patients may
progress to FSGS
MEMBRANOUS GN
⦁ Incidence: 40-60 Years, 50% of
adult nephrotic syndrome
⦁ Etiology: Idiopathic in most
patients, associated with
infections, drugs, carcinomas, and
heavy metals.
⦁ Path: Diffuse, uniform BM
thickening with subepithelial
projections (“spikes”). Diffuse,
coarsely granular IgG and C3
deposits along basement
membranes. Electron-dense
subepithelial deposits
MEMBRANOUS GN
⦁ Clinical: Nephrotic syndrome in 80%, asymptomatic
proteinuria in 20%.
⦁ Lab: Microscopic hematuria. Non-selective proteinuria ±
hematuria.
⦁ Clinical Course Excellent prognosis in children. Some
adults develop ESRD. Exclusion of other diseases is
required
MEMBRANOPROLIFERATIVE GN :
Chronic immune
⦁ Etiology:
complex GN. Associated with
chronic infections, SLE, cancer,
cirrhosis, heroin abuse, etc.
⦁ Incidence: Children and young
adults (5-25 years
⦁ Path: Diffuse proliferative GN
with thickening of the glomerular
capillary walls,, and GBM splitting
(“tram-tracking”). Diffuse,
coarsely granular C3 and IgG
deposits along GBMs. Electron-
dense subendothelial deposits.
MEMBRANOPROLIFERATIVE GN :
⦁ Clinical: Nephrotic syndrome in 50%, acute nephritic
syndrome in 20%. Recent history of URI in 50%.
Hypertension and/or renal insufficiency.
⦁ Lab: Hypocomplementemia of classic and alternate
pathways. C3 nephritic factor (C3NEF). Circulating
immune complexes.
⦁ Clinical Course: Progressive deterioration of renal
function ± short remissions. ESRD within 10 years in
50% of children and 80% of adults.
DIABETIC NEPHROPATHY
⦁ Nephropathy complicates 30% of cases
of type I DM and approximately 20% of
cases type II DM.
⦁ Supportive clues are the presence of
normal sized or enlarged kidneys,
proliferative diabetic
and a bland urinary
evidence,
retinopathy,
sediments.
⦁ Retinopathy is found in 90% and 60%
of patients with type I and type II DM
⦁ The earliest morphologic abnormalities
nephropathy are thickening of the GBM
and expansion mesangium
⦁ Prominent nodular matrix expansion
(classical Kimmelsteil-Wilson lesion)
are often found.
THANKS!

More Related Content

Similar to nephroticsyndromeabhay-copy-140910103817-phpapp02 (1).pptx

Nephrotic syndrome (Primary glomerulonephrosis)
Nephrotic syndrome (Primary glomerulonephrosis)Nephrotic syndrome (Primary glomerulonephrosis)
Nephrotic syndrome (Primary glomerulonephrosis)kalyan kumar
 
Nephrotic syndrome final
Nephrotic syndrome finalNephrotic syndrome final
Nephrotic syndrome finalakilav99
 
Nephrotic syndrome final shivaom
Nephrotic syndrome final shivaomNephrotic syndrome final shivaom
Nephrotic syndrome final shivaomShivaom Chaurasia
 
Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndromeSachin Verma
 
Nephortic syndrome
Nephortic syndromeNephortic syndrome
Nephortic syndromeANILKUMAR BR
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome AZu SA
 
Overview of management of nephrotic syndrom
Overview of management of nephrotic syndromOverview of management of nephrotic syndrom
Overview of management of nephrotic syndromOgechukwu Uzoamaka Mbanu
 
Nephrosis 2009,
Nephrosis 2009,Nephrosis 2009,
Nephrosis 2009,Deep Deep
 
Glomerulonephritis and nephrotic sydrome
Glomerulonephritis and nephrotic sydromeGlomerulonephritis and nephrotic sydrome
Glomerulonephritis and nephrotic sydromeIram Anwar
 
Nephrotic Syndrome.pptx
Nephrotic  Syndrome.pptxNephrotic  Syndrome.pptx
Nephrotic Syndrome.pptxGrashiaBlessy1
 
Generalized oedema & Proteinuria
Generalized oedema & ProteinuriaGeneralized oedema & Proteinuria
Generalized oedema & ProteinuriaMohammed Musa
 
Glomerulonephropathy PGY 1.pptx
Glomerulonephropathy PGY 1.pptxGlomerulonephropathy PGY 1.pptx
Glomerulonephropathy PGY 1.pptxraeeskoio
 

Similar to nephroticsyndromeabhay-copy-140910103817-phpapp02 (1).pptx (20)

Nephrotic syndrome (Primary glomerulonephrosis)
Nephrotic syndrome (Primary glomerulonephrosis)Nephrotic syndrome (Primary glomerulonephrosis)
Nephrotic syndrome (Primary glomerulonephrosis)
 
NEPHROTIC SYNDROME-3.pptx
NEPHROTIC SYNDROME-3.pptxNEPHROTIC SYNDROME-3.pptx
NEPHROTIC SYNDROME-3.pptx
 
Nephrotic syndrome final
Nephrotic syndrome finalNephrotic syndrome final
Nephrotic syndrome final
 
Nephrotic syndrome final shivaom
Nephrotic syndrome final shivaomNephrotic syndrome final shivaom
Nephrotic syndrome final shivaom
 
Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndrome
 
Nephortic syndrome
Nephortic syndromeNephortic syndrome
Nephortic syndrome
 
Hematuria.docx
Hematuria.docxHematuria.docx
Hematuria.docx
 
Nephrotic syndrome
Nephrotic syndrome Nephrotic syndrome
Nephrotic syndrome
 
Overview of management of nephrotic syndrom
Overview of management of nephrotic syndromOverview of management of nephrotic syndrom
Overview of management of nephrotic syndrom
 
Medicine 5th year, 6th & 7th lectures (Dr. Rasool)
Medicine 5th year, 6th & 7th lectures (Dr. Rasool)Medicine 5th year, 6th & 7th lectures (Dr. Rasool)
Medicine 5th year, 6th & 7th lectures (Dr. Rasool)
 
NS and NS.pptx
NS and NS.pptxNS and NS.pptx
NS and NS.pptx
 
NS and NS.pptx
NS and NS.pptxNS and NS.pptx
NS and NS.pptx
 
Nephrosis 2009,
Nephrosis 2009,Nephrosis 2009,
Nephrosis 2009,
 
Glomerulonephritis and nephrotic sydrome
Glomerulonephritis and nephrotic sydromeGlomerulonephritis and nephrotic sydrome
Glomerulonephritis and nephrotic sydrome
 
Nephroti1
Nephroti1Nephroti1
Nephroti1
 
Nephrotic Syndrome.pptx
Nephrotic  Syndrome.pptxNephrotic  Syndrome.pptx
Nephrotic Syndrome.pptx
 
Generalized oedema & Proteinuria
Generalized oedema & ProteinuriaGeneralized oedema & Proteinuria
Generalized oedema & Proteinuria
 
Glomerulonephropathy PGY 1.pptx
Glomerulonephropathy PGY 1.pptxGlomerulonephropathy PGY 1.pptx
Glomerulonephropathy PGY 1.pptx
 
Proteinuria & Hematuria
Proteinuria & HematuriaProteinuria & Hematuria
Proteinuria & Hematuria
 
5GN.pptx
5GN.pptx5GN.pptx
5GN.pptx
 

More from debasmitamahanti1

More from debasmitamahanti1 (12)

sbar lakhmi.pptx
sbar lakhmi.pptxsbar lakhmi.pptx
sbar lakhmi.pptx
 
result analysis 2019.pptx
result analysis 2019.pptxresult analysis 2019.pptx
result analysis 2019.pptx
 
Another_First_Aid.pptx
Another_First_Aid.pptxAnother_First_Aid.pptx
Another_First_Aid.pptx
 
Basic_First_Aid_0808.pptx
Basic_First_Aid_0808.pptxBasic_First_Aid_0808.pptx
Basic_First_Aid_0808.pptx
 
ATERIAL BLOOD GASES.pptx
ATERIAL BLOOD GASES.pptxATERIAL BLOOD GASES.pptx
ATERIAL BLOOD GASES.pptx
 
epilepsy-131129104031-phpapp01 (1).pptx
epilepsy-131129104031-phpapp01 (1).pptxepilepsy-131129104031-phpapp01 (1).pptx
epilepsy-131129104031-phpapp01 (1).pptx
 
afdd773b971eeb939b80bc2647168d55.pptx
afdd773b971eeb939b80bc2647168d55.pptxafdd773b971eeb939b80bc2647168d55.pptx
afdd773b971eeb939b80bc2647168d55.pptx
 
8b146f83f8b0f7368a294618ff653a30.pptx
8b146f83f8b0f7368a294618ff653a30.pptx8b146f83f8b0f7368a294618ff653a30.pptx
8b146f83f8b0f7368a294618ff653a30.pptx
 
chemotherapy access device.pptx
chemotherapy access device.pptxchemotherapy access device.pptx
chemotherapy access device.pptx
 
pediatric circulation.pptx
pediatric circulation.pptxpediatric circulation.pptx
pediatric circulation.pptx
 
clinical outcome ped.pptx
clinical outcome ped.pptxclinical outcome ped.pptx
clinical outcome ped.pptx
 
QUIZ.pptx
QUIZ.pptxQUIZ.pptx
QUIZ.pptx
 

Recently uploaded

Units of Radiation Measurements, Quality Specification, Half-Value Thickness,...
Units of Radiation Measurements, Quality Specification, Half-Value Thickness,...Units of Radiation Measurements, Quality Specification, Half-Value Thickness,...
Units of Radiation Measurements, Quality Specification, Half-Value Thickness,...Dr. Dheeraj Kumar
 
CPCSEA guidelines and IAEC committee.pptx
CPCSEA guidelines and IAEC committee.pptxCPCSEA guidelines and IAEC committee.pptx
CPCSEA guidelines and IAEC committee.pptxMs. Kiran Divekar
 
Plasma proteins and their functions for Nursing .pptx
Plasma proteins and their functions for Nursing .pptxPlasma proteins and their functions for Nursing .pptx
Plasma proteins and their functions for Nursing .pptxRajendra Dev Bhatt
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Musculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxMusculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxraviapr7
 
Rapid Release Granulation Technology ppt
Rapid Release Granulation Technology pptRapid Release Granulation Technology ppt
Rapid Release Granulation Technology pptHasnat Tariq
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Presentation on Non Steroidal Anti-inflammatory Agents
Presentation on Non Steroidal Anti-inflammatory AgentsPresentation on Non Steroidal Anti-inflammatory Agents
Presentation on Non Steroidal Anti-inflammatory AgentsPrerana Jadhav
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Prince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxPrince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxprincebieber28
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
Heme synthesis for medical And Nursing studentspptx
Heme synthesis for medical And Nursing studentspptxHeme synthesis for medical And Nursing studentspptx
Heme synthesis for medical And Nursing studentspptxRajendra Dev Bhatt
 
23470206-Esophageal-Cancer.ppt for medical surgical nursing
23470206-Esophageal-Cancer.ppt for medical surgical nursing23470206-Esophageal-Cancer.ppt for medical surgical nursing
23470206-Esophageal-Cancer.ppt for medical surgical nursingakoeljames8543
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfDivya Kanojiya
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxEx WHO/USAID
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 

Recently uploaded (20)

Units of Radiation Measurements, Quality Specification, Half-Value Thickness,...
Units of Radiation Measurements, Quality Specification, Half-Value Thickness,...Units of Radiation Measurements, Quality Specification, Half-Value Thickness,...
Units of Radiation Measurements, Quality Specification, Half-Value Thickness,...
 
CPCSEA guidelines and IAEC committee.pptx
CPCSEA guidelines and IAEC committee.pptxCPCSEA guidelines and IAEC committee.pptx
CPCSEA guidelines and IAEC committee.pptx
 
Plasma proteins and their functions for Nursing .pptx
Plasma proteins and their functions for Nursing .pptxPlasma proteins and their functions for Nursing .pptx
Plasma proteins and their functions for Nursing .pptx
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Musculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxMusculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptx
 
JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-
 
Rapid Release Granulation Technology ppt
Rapid Release Granulation Technology pptRapid Release Granulation Technology ppt
Rapid Release Granulation Technology ppt
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Presentation on Non Steroidal Anti-inflammatory Agents
Presentation on Non Steroidal Anti-inflammatory AgentsPresentation on Non Steroidal Anti-inflammatory Agents
Presentation on Non Steroidal Anti-inflammatory Agents
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Navigating Advances in Alzheimer’s Disease: An Expert Consult on Integrating ...
Navigating Advances in Alzheimer’s Disease: An Expert Consult on Integrating ...Navigating Advances in Alzheimer’s Disease: An Expert Consult on Integrating ...
Navigating Advances in Alzheimer’s Disease: An Expert Consult on Integrating ...
 
Prince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptxPrince Paulraj W HERBAL DRUG TECHNO.pptx
Prince Paulraj W HERBAL DRUG TECHNO.pptx
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
Heme synthesis for medical And Nursing studentspptx
Heme synthesis for medical And Nursing studentspptxHeme synthesis for medical And Nursing studentspptx
Heme synthesis for medical And Nursing studentspptx
 
23470206-Esophageal-Cancer.ppt for medical surgical nursing
23470206-Esophageal-Cancer.ppt for medical surgical nursing23470206-Esophageal-Cancer.ppt for medical surgical nursing
23470206-Esophageal-Cancer.ppt for medical surgical nursing
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdf
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptx
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 

nephroticsyndromeabhay-copy-140910103817-phpapp02 (1).pptx

  • 2. Definition Nephrotic syndrome is a clinical complex characterized by a number of renal and extrarenal features, most prominent of which are  Proteinuria (in practice > 3.0 to 3.5gm/24hrs),  Hypoalbuminemia,  Edema,  Hypertension  Hyperlipidemia,  Lipiduria and  Hypercoagulabilty.
  • 3.
  • 4. Classification Nephrotic syndrome can be ⦁ Primary, being a disease specific to the kidneys, ⦁ Secondary, being a renal manifestation of a systemic general illness
  • 5. Primary causes Primary causes include- ⦁ Minimal-change nephropathy(70-90% children and 10- 15%inadult) ⦁ Focal glomerulosclerosis (15%inadult) ⦁ Membranous nephropathy (30%inadult) ⦁ Mesangial proliferative glomerulonephritis . ⦁ Rapidly progressive glomerulonephritis
  • 6. Secondary causes Secondary causes include- ⦁ Diabetes mellitus ⦁ Lupus erythematosus ⦁ Amyloidosis and paraproteinemias ⦁ Viral infections (eg, hepatitis B, hepatitis C, HIV ) ⦁ Preeclampsia
  • 7. ⦁ Nephrotic syndrome is 15 times more common in children ⦁ Most cases in children are due to minimal-change disease. ⦁ In adults, the most common form is membranous glomerulonephritis, followed by FSGS. ⦁ Diabetic nephropathy is emerging as a major cause of nephrotic syndrome
  • 10. Pathophysiology of proteinuria ⦁ In a healthy individual, less than 0.1% of pl. albumin may traverse the glomerular filtration barrier. ⦁ glomerular capillaries are lined by a fenestrated endothelium that sits on the glomerular basement membrane ⦁ Which in turn is covered by glomerular epithelium, or podocytes, which envelops the capillaries with cellular extensions called foot processes. In between the foot processes are the filtration slits. ⦁ These 3 structures are the glomerular filtration barrier
  • 11. Pathophysiology of proteinuria ⦁ The glomerular structural changes that may cause proteinuria are damage to the endothelial surface, the glomerular basement membrane, or the podocytes. ⦁ Glomerular haemodynamics (Intraglomerular hypertension and hyperfiltration) can alter Glomerular permeabiality. ⦁ Selectivity of proteinuria- Excretion of relatively low M.W. protein (Albumin or transferrin) is known as selective proteinuria while if excretion is predominately high M.W. protein (IgG, IgM or α2 macroglobulin) it is nonselective proteinuria. ⦁ It is also related to relative damage of Glomerular filter.
  • 12. Hypoalbunemia ⦁ It is due to both the proteinuria and due to the increase renal catabolism (in tubules). ⦁ In fact hepatic albumin synthesis is increased from 145±9mg/kg/day to 213±17mg/kg/day in nephrotic patients.
  • 14. Metabolic consequences of proteinuria Metabolic consequences of the nephrotic syndrome include the following: ⦁ Infection ⦁ Hyperlipidemia and atherosclerosis ⦁ Hypocalcemia and bone abnormalities ⦁ Hypercoagulability ⦁ Hypovolemia
  • 15. Proposed explanations of Infection in NS Proposed explanations include the following: ⦁ Urinary immunoglobulin losses ⦁ Edema fluid acting as a culture medium ⦁ Protein deficiency ⦁ Decreased bactericidal activity of the leukocytes ⦁ Immunosuppressive therapy ⦁ Urinary loss of a complement factor (properdin factor B) that opsonizes certain bacteria
  • 16. Hypperlipedemia ⦁ Due to increase hepatic lipoprotein synthesis that is triggered by reduced oncotic . ⦁ Defective lipid catabolism has also important role. ⦁ LDL and cholesterol are increased in majority of patients whereas VLDL and triglyceride tends to rise in patients with severe disease. ⦁ It increases the relative risk for MI 5.5 fold and coronary death 2.8 fold. ⦁ It also increases progression of renal disease
  • 17. Hypercoagulability ⦁ Multifactorial in origin ⦁ Increase urinary loss of antithrombin III. ⦁ Altered levels and/or activity of protein C & S. ⦁ Hyperfibronogenemia due to increase hepatic synthesis. ⦁ Impaired fibrinolysis due to decrease plasminogen. ⦁ Increase platelet aggregability – relative immobility - haemoconcentragtion from hypovolemia. – hyperlipidemia ⦁ Alteration in endothelial function
  • 18. Hypocalcemia ⦁ Hypocalcemia is common in the nephrotic syndrome, but rather than being a true hypocalcemia, it is usually caused by a low serum albumin level. ⦁ Nonetheless, low bone density and abnormal bone histology are reported in association with nephrotic syndrome. ⦁ This could be caused by urinary losses of vitamin D– binding proteins, with consequent hypovitaminosis D and, as a result, reduced intestinal calcium absorption.
  • 19. Hypovolemia ⦁ Hypovolemia occurs when hypoalbuminemia decreases the plasma oncotic pressure, ⦁ Resulting in a loss of plasma water into the interstitium and causing a decrease in circulating blood volume. ⦁ Hypovolemia is generally observed only when the patient's serum albumin level is less than 1.5 g/dL. ⦁ Hypotension is a late feature
  • 20. FUNCTIONAL CONSEQUENCE OF URINARY LOSS OF PLASMA PROTEIN ⦁ Thyroid binding globulins and thyroxin – may lead to hypothyroidism. ⦁ Vit D binding protein – oesteomalacia, but rare ⦁ Total calcium is also low due to low albumin level. ⦁ Transferrin and erythropoietin and – microcytic hypochromic anemia. ⦁ ARF – is rare in nephrotic syndrome. In whom it occur patient are elderly of minimal changes disease / FGSS
  • 21. Symptoms and signs ⦁ Include anorexia, malaise, puffy eyelids, retinal sheen, abdominal pain, wasting of muscles, and edema. ⦁ Most often, the edema is mobile - detected in the eyelids in the morning and in the ankles after ambulation ⦁ Focal edema may be the reason for seeking help complaints as:  difficulty breathing (pleural effusion or laryngeal edema),  substernal chest pain (pericardial effusion),  scrotal swelling,  swollen knees (hydroarthrosis),  swollen abdomen (ascites), and for such  abdominal pain from edema of the mesentery.
  • 22. Symptoms and signs ⦁ An early sign of NS is frothy urine. ⦁ At presentation,proteinuria is usually > 2 gm/m2/day, or a urine protein/creatinine ratio is > 2 ⦁ Orthostatic hypotension and even shock may develop in children. ⦁ Adults may be hypo-, normo-, or hypertensive. ⦁ Oliguria and even ⦁ Acute renal failure may develop because of hypovolemia and diminished perfusion.
  • 23. Symptoms and signs ⦁ Prolonged NS may result in nutritional deficiencies, including protein malnutrition ⦁ ,myopathy, ⦁ Decreased total Ca++, tetany ⦁ Spontaneous peritonitis and opportunistic infections ⦁ Coagulation disorders, with decreased fibrinolytic activity ⦁ Episodic hypovolemia, are a serious thrombotic risk ( renal vein thrombosis). ⦁ Hypertension with cardiac and cerebral complications.
  • 24. Differential Diagnosis ⦁ Heart failure ⦁ Cirrhosis ⦁ Glomerulonephritis
  • 25. Workup Diagnostic studies for nephrotic syndrome may include the following: ⦁ Urinalysis ⦁ Urine sediment examination ⦁ Urinary protein measurement (24-hr) ⦁ Serum albumin ⦁ Serologic studies for infection and immune abnormalities ⦁ Renal ultrasonography ⦁ Renal biopsy
  • 26. IMPORTANT DEFINITIONS ⦁ RESPONSE; protein free urine on 3 consecutive days within 7 days. ⦁ RELAPSE; protein +ve urine on 3 consecutive days within one week with edema. ⦁ FREQUENT RELAPSING NS; steroid sensitive nephrotic syndrome with 2 or more relapses in 6 months or more than 3 in one year. ⦁ STEROID DEPENDANT; responder who relapses while steroid is being tapered or within 14 days of stopping steroid treatment. ⦁ INITIAL NON RESONDER; no response during initial 8 weeks of therapy. ⦁ LATE NON RESPONDER; an initial steroid responder who fails to respond to 4 week treatment in relapse.
  • 27. Management ⦁ Specific treatment ⦁ In minimal-change nephropathy, glucocorticosteroids, such as prednisone, are used. Children who relapse may be treated with rituximab] ⦁ In some lupus nephritis, prednisone and cyclophosphamide are useful ⦁ Secondary amyloidosis with nephrotic syndrome may respond to inflammatory treatment of the primary disease. anti- ⦁ In membranous nephropathy, expectant management without immunosuppression can be used for the first 6 months, in patients at low risk for progression (ie, those with serum creatinine level < 1.5 mg/dL). Patients with renal insufficiency (serum creatinine level > 1.5 mg/dL) are at greatest risk for the development of end-stage renal disease and should receive immunosuppressive therapy.[37]
  • 28. Management Diet and activity ⦁ The diet in patients with nephrotic syndrome should provide adequate energy (caloric) intake and adequate protein (1-2 g/kg/d). ⦁ A diet with no added salt will help to limit fluid overload. ⦁ Management of hyperlipidemia could be of some importance if the nephrotic state is prolonged. ⦁ Fluid restriction per se is not required. ⦁ Ongoing activity, rather than bed rest, will reduce the risk of blood clots.
  • 29. Management Acute Nephrotic Syndrome in Adults ⦁ Diuretics will be needed; furosemide, spironolactone, and even metolazone may be used. Volume depletion may occur with diuretic use, which should be monitored. ⦁ Anticoagulation has been advocated by some for use in preventing thromboembolic complications, ⦁ Hypolipidemic agents may be used, but if the nephrotic syndrome cannot be controlled, the patient will have persistent hyperlipidemia. ⦁ ACE inhibitors and/or ARB are widely used. These may reduce proteinuria by reducing the systemic blood pressure, by reducing intraglomerular pressure, and also by direct action on podocytes.
  • 30. Management ⦁ Long-Term Monitoring- Follow-up care in patients with nephrotic syndrome includes ⦁ Immunization, ⦁ Treatment of relapses of steroid-responsive nephrotic syndromes, ⦁ Monitoring for steroid toxicity, and ⦁ Monitoring of diuretic and angiotensin antagonist regimens.
  • 31. Medication Summary ⦁ Corticosteroids (prednisone), ⦁ Cyclophosphamide, ⦁ Cyclosporine ⦁ Rituximab ⦁ Mycophenolate ⦁ Diuretics ⦁ ACE inhibitors and ⦁ ARB
  • 33. MINIMAL CHANGE GN ⦁ Introduction Synonyms: Nil disease, lipoid nephrosis, foot process disease ⦁ Incidence: 80% of nephrotic syndrome in children (1-8 yrs.), mostly male. Adults in 2nd-3rd decade ⦁ Etiology: Idiopathic. Loss of net negative charge on capillary basement membrane ⦁ Pathology: LM - Normal. IF - Negative. EM - Focal fusion/loss of foot processes.
  • 34. MINIMAL CHANGE GN ⦁ Clinical Features: : Nephrotic syndrome. History of recent URI in 30%. Association with Hodgkin’s lymphoma Overlap with FSGS patients ⦁ Lab Features: Selective proteinuria. No specific laboratory findings. ⦁ Clinical Course.. Spontaneous remission in 25-40%. Complete remission in 65-70% of patients. Steroid resistant patients may progress to FSGS
  • 35. MEMBRANOUS GN ⦁ Incidence: 40-60 Years, 50% of adult nephrotic syndrome ⦁ Etiology: Idiopathic in most patients, associated with infections, drugs, carcinomas, and heavy metals. ⦁ Path: Diffuse, uniform BM thickening with subepithelial projections (“spikes”). Diffuse, coarsely granular IgG and C3 deposits along basement membranes. Electron-dense subepithelial deposits
  • 36. MEMBRANOUS GN ⦁ Clinical: Nephrotic syndrome in 80%, asymptomatic proteinuria in 20%. ⦁ Lab: Microscopic hematuria. Non-selective proteinuria ± hematuria. ⦁ Clinical Course Excellent prognosis in children. Some adults develop ESRD. Exclusion of other diseases is required
  • 37. MEMBRANOPROLIFERATIVE GN : Chronic immune ⦁ Etiology: complex GN. Associated with chronic infections, SLE, cancer, cirrhosis, heroin abuse, etc. ⦁ Incidence: Children and young adults (5-25 years ⦁ Path: Diffuse proliferative GN with thickening of the glomerular capillary walls,, and GBM splitting (“tram-tracking”). Diffuse, coarsely granular C3 and IgG deposits along GBMs. Electron- dense subendothelial deposits.
  • 38. MEMBRANOPROLIFERATIVE GN : ⦁ Clinical: Nephrotic syndrome in 50%, acute nephritic syndrome in 20%. Recent history of URI in 50%. Hypertension and/or renal insufficiency. ⦁ Lab: Hypocomplementemia of classic and alternate pathways. C3 nephritic factor (C3NEF). Circulating immune complexes. ⦁ Clinical Course: Progressive deterioration of renal function ± short remissions. ESRD within 10 years in 50% of children and 80% of adults.
  • 39. DIABETIC NEPHROPATHY ⦁ Nephropathy complicates 30% of cases of type I DM and approximately 20% of cases type II DM. ⦁ Supportive clues are the presence of normal sized or enlarged kidneys, proliferative diabetic and a bland urinary evidence, retinopathy, sediments. ⦁ Retinopathy is found in 90% and 60% of patients with type I and type II DM ⦁ The earliest morphologic abnormalities nephropathy are thickening of the GBM and expansion mesangium ⦁ Prominent nodular matrix expansion (classical Kimmelsteil-Wilson lesion) are often found.